Attempting to Update NYSEAMERICAN:PTN with AlphaVantage
Updated NYSEAMERICAN:PTN with AlphaVantage to 0.9063
Calculated RSI to 64.0293637846656
NYSEAMERICAN:PTN - Stock Price, News, & Analysis for Palatin Technologies

NYSEAMERICAN:PTN - Palatin Technologies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.9063 +0.01 (+1.12 %)
(As of 10/22/2018 09:47 AM ET)
Previous Close$0.8945
Today's Range$0.90 - $0.92
52-Week Range$0.72 - $1.59
Volume59,482 shs
Average Volume1.59 million shs
Market Capitalization$184.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL­3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Receive PTN News and Ratings via Email

Sign-up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:PTN
CUSIPN/A
Phone+1-609-4952200

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins28.55%
Return on Equity155.80%
Return on Assets27.77%

Miscellaneous

Employees19
Outstanding Shares202,050,000
Market Cap$184.13 million

Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions

What is Palatin Technologies' stock symbol?

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) announced its quarterly earnings data on Thursday, September, 13th. The biopharmaceutical company reported $0.06 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.00 by $0.06. The biopharmaceutical company had revenue of $20.62 million for the quarter, compared to analyst estimates of $6.03 million. Palatin Technologies had a net margin of 28.55% and a return on equity of 155.80%. During the same period in the prior year, the firm posted ($0.02) EPS. View Palatin Technologies' Earnings History.

When is Palatin Technologies' next earnings date?

Palatin Technologies is scheduled to release their next quarterly earnings announcement on Monday, November 12th 2018. View Earnings Estimates for Palatin Technologies.

What price target have analysts set for PTN?

4 equities research analysts have issued 1-year price targets for Palatin Technologies' stock. Their predictions range from $2.00 to $6.00. On average, they expect Palatin Technologies' stock price to reach $4.00 in the next year. This suggests a possible upside of 341.4% from the stock's current price. View Analyst Price Targets for Palatin Technologies.

What is the consensus analysts' recommendation for Palatin Technologies?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Palatin Technologies.

Are investors shorting Palatin Technologies?

Palatin Technologies saw a drop in short interest in September. As of September 28th, there was short interest totalling 13,329,748 shares, a drop of 4.1% from the September 14th total of 13,893,891 shares. Based on an average daily volume of 854,558 shares, the days-to-cover ratio is currently 15.6 days. Currently, 7.0% of the company's shares are short sold. View Palatin Technologies' Current Options Chain.

Who are some of Palatin Technologies' key competitors?

Who are Palatin Technologies' key executives?

Palatin Technologies' management team includes the folowing people:
  • Dr. John K. A. Prendergast, Co-Founder & Non-Exec. Chairman (Age 64)
  • Dr. Carl Spana, Co-Founder, Pres, CEO & Director (Age 56)
  • Mr. Stephen T. Wills CPA, MST, CFO, COO, Exec. VP, Treasurer & Sec. (Age 61)
  • Burns McClellan, VP of Investor Relations

How do I buy shares of Palatin Technologies?

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Palatin Technologies' stock price today?

One share of PTN stock can currently be purchased for approximately $0.9063.

How big of a company is Palatin Technologies?

Palatin Technologies has a market capitalization of $184.13 million. Palatin Technologies employs 19 workers across the globe.

What is Palatin Technologies' official website?

The official website for Palatin Technologies is http://www.palatin.com/.

How can I contact Palatin Technologies?

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.


MarketBeat Community Rating for Palatin Technologies (NYSEAMERICAN PTN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  273 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  483
MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe PTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel